Efficacy of intraperitoneal chemohyperthermia with oxaliplatin in colorectal peritoneal carcinomatosis.: Preliminary results in 24 patients

被引:74
|
作者
Elias, D
Sideris, L
Pocard, M
Edè, C
Ben Hassouna, D
Ducreux, M
Boige, V
Côté, JF
Lasser, P
机构
[1] Inst Gustave Roussy, Dept Surg Oncol, Villejuif, France
[2] Inst Gustave Roussy, Intens Care Unit, Villejuif, France
[3] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[4] Inst Gustave Roussy, Dept Pathol, Villejuif, France
关键词
colorectal; intraperitoneal chemohyperthermia; oxaliplatin; peritoneal carcinomatosis; surgery;
D O I
10.1093/annonc/mdh186
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The complete resection of macroscopic colorectal peritoneal carcinomatosis (PC), followed by intraoperative intraperitoneal chemohyperthermia (IPCH) to treat residual microscopic disease, leads to cure in some patients. We report preliminary results on survival in a phase II study using oxaliplatin (LOHP). Patients and methods: Twenty-four patients with macroscopic colorectal PC underwent complete resection of the PC followed by IPCH with LOHP performed in an open abdominal cavity. The dose of LOHP was 460 mg/m(2) in 21/m(2), during 30 min at 43degreesC, at a flow rate of 21/min. During the hour preceding IPCH, they received an intravenous administration of 5-fluorouracil (400 mg/m(2)) and leucovorin (20 mg/m(2)). Results: Mean peritoneal tumoral extension (Sugarbaker's Index) was 16.9 +/- 9.5, median operative duration was 490 min and median blood loss was 965 ml. There were two postoperative deaths (8%) by intracerebral hemorrhage, and morbidity rate was 41.6%. Minimal follow-up was 18 months and median follow-up was 27.4 months (range 18.3-49.6). At 1, 2 and 3 years, overall survival rates were 83%, 74% and 65%, and disease-free survival rates were 70%, 50% and 50%, respectively. Only 32% of the 22 postoperative living patients presented a peritoneal recurrence. A peritoneal index >24 influenced survival, with a 17% recurrence rate at 2 years versus 63% when it was <24 (P = 0.005). Conclusion: This new modality of treatment, when feasible, gives encouraging preliminary results, with a promising 3-year survival rate of 65%.
引用
收藏
页码:781 / 785
页数:5
相关论文
共 50 条
  • [21] Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin for Peritoneal Carcinomatosis Arising from Appendix: Preliminary Results of a Survival Analysis
    Eric Marcotte
    Lucas Sideris
    Pierre Drolet
    Andrew Mitchell
    Suzanne Frenette
    Guy Leblanc
    Yves E. Leclerc
    Pierre Dubé
    Annals of Surgical Oncology, 2008, 15 : 2701 - 2708
  • [22] Peritoneal carcinomatosis. Surgical treatment, including hyperthermal intraperitoneal chemotherapy
    Glockzin, G.
    Ghall, N.
    Lang, S. A.
    Agha, A.
    Schlitt, H. J.
    Piso, P.
    CHIRURG, 2007, 78 (12): : 1100 - +
  • [23] Preoperative intraperitoneal oxaliplatin for unresectable peritoneal carcinomatosis of colorectal origin: a pilot study
    Sgarbura, Olivia
    Samalin, Emmanuelle
    Carrere, Sebastien
    Mazard, Thibault
    de Forges, Helene
    Alline, Mathias
    Pissas, Marie-Helene
    Portales, Fabienne
    Ychou, Marc
    Quenet, Francois
    PLEURA AND PERITONEUM, 2016, 1 (04) : 209 - 215
  • [24] Safety and Efficacy of Hyperthermic Intraperitoneal Chemoperfusion with High-Dose Oxaliplatin in Patients with Peritoneal Carcinomatosis
    Wim P. Ceelen
    Marc Peeters
    Philippe Houtmeyers
    Christophe Breusegem
    Filip De Somer
    Piet Pattyn
    Annals of Surgical Oncology, 2008, 15 : 535 - 541
  • [25] Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis
    Ceelen, Wim P.
    Peeters, Marc
    Houtmeyers, Philippe
    Breusegem, Christophe
    De Somer, Filip
    Pattyn, Piet
    ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (02) : 535 - 541
  • [26] Abdominal cancer with peritoneal carcinomatosis treated by peritonectomy procedure and intraperitoneal chemohyperthermia
    Glehen, O
    Peyrat, P
    Beaujard, A
    Caillot, JL
    Francois, Y
    Gueugniaud, PY
    Garbit, F
    Bienvenu, J
    Vignal, J
    Gilly, FN
    EXPERIMENTAL ONCOLOGY, 2000, 22 (1-2): : 59 - 63
  • [27] INTRAPERITONEAL-FREE CANCER CELLS REPRESENT A MAJOR PROGNOSTIC FACTOR IN COLORECTAL PERITONEAL CARCINOMATOSIS.
    Trilling, B.
    Cotte, E.
    Vaudoyer, D.
    Glehen, O.
    Passot, G.
    DISEASES OF THE COLON & RECTUM, 2016, 59 (05) : E196 - E196
  • [28] Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with oxaliplatin in colorectal Carcinoma with advanced Peritoneal Carcinomatosis: Initial clinical Results
    Reymond, M.
    Giger-Pabst, U.
    Solass, W.
    Strumberg, D.
    Zieren, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 48 - 49
  • [29] Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC
    van Eden, W. J.
    Kok, N. F. M.
    Woensdregt, K.
    Huitema, A. D. R.
    Boot, H.
    Aalbers, A. G. J.
    EJSO, 2018, 44 (02): : 220 - 227
  • [30] Efficacy and safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in women with recurrent gynaecological cancer and peritoneal carcinomatosis.
    Reymond, Marc A.
    Solass, Wiebke
    Giger-Pabst, Urs
    Strumberg, Dirk
    Zieren, Jurgen
    Tempfer, Clemens
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)